Reprogramming human T cell function and specificity with non-viral genome targeting

[1]  A. Scharenberg,et al.  Therapeutic Gene Editing Safety and Specificity. , 2017, Hematology/oncology clinics of North America.

[2]  Andreas Reinisch,et al.  Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6 , 2017, eLife.

[3]  Howard Y. Chang,et al.  Discovery of stimulation-responsive immune enhancers with CRISPR activation , 2017, Nature.

[4]  Jonathan S. Weissman,et al.  Design and specificity of long ssDNA donors for CRISPR-based knock-in , 2017, bioRxiv.

[5]  Michel Sadelain,et al.  Therapeutic T cell engineering , 2017, Nature.

[6]  Yutaka Inagaki,et al.  Easi-CRISPR: a robust method for one-step generation of mice carrying conditional and insertion alleles using long ssDNA donors and CRISPR ribonucleoproteins , 2017, Genome Biology.

[7]  Wendell A Lim,et al.  Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. , 2017, Annual review of immunology.

[8]  Graham Dellaire,et al.  Marker-free coselection for CRISPR-driven genome editing in human cells , 2017, Nature Methods.

[9]  Claudio Mussolino,et al.  Refining strategies to translate genome editing to the clinic , 2017, Nature Medicine.

[10]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[11]  S. Rosenberg,et al.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations , 2017, Nature Immunology.

[12]  W. Lim,et al.  The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.

[13]  A. Scharenberg,et al.  Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells , 2017, Molecular therapy. Methods & clinical development.

[14]  S. Warming,et al.  Efficient mapping of transgene integration sites and local structural changes in Cre transgenic mice using targeted locus amplification , 2017, Nucleic acids research.

[15]  Steven Henikoff,et al.  An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites , 2016, bioRxiv.

[16]  Edward M. Callaway,et al.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.

[17]  Sruthi Mantri,et al.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.

[18]  Bo Huang,et al.  A scalable strategy for high-throughput GFP tagging of endogenous human proteins , 2016, Proceedings of the National Academy of Sciences.

[19]  Jennifer A. Doudna,et al.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.

[20]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[21]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[22]  M. Daly,et al.  Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants , 2014, Nature.

[23]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[24]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[25]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[26]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[27]  A. Rudensky,et al.  Regulatory T cells and Foxp3 , 2011, Immunological reviews.

[28]  V. Hornung,et al.  Intracellular DNA recognition , 2010, Nature Reviews Immunology.

[29]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[30]  H. Dadi,et al.  Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor , 1997 .

[31]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[32]  J. Murnane,et al.  Recombination events during integration of transfected DNA into normal human cells. , 1990, Nucleic acids research.

[33]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[34]  F. Cosset,et al.  Lentiviral vector gene transfer into human T cells. , 2009, Methods in molecular biology.

[35]  S. Rosenberg,et al.  High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  H. Dadi,et al.  Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.